The purpose of this study is to explore the different efficacy and safety profile of secukinumab 300 mg in patients with moderate to severe chronic plaque-type psoriasis, stratified for the presence of HLA-C*06, whose determination will be blinded for patients and investigators. The study will be conducted both on anti-TNFα-naïve and anti-TNFα failure patients and will also stratify for TNFα - 308 polymorphism, BMI, smoking and metabolic syndrome, among others.